| Focus | Biotech companies focused on drug discovery, development or delivery |
| Geography | Global, especially North America and Europe |
| Stage | Preclinical development through clinical proof-of-concept |
| Size | From $500K up to $5MM per round |
| Board Role | Board of directors seat or observer rights, consistent with ownership amount |
| Syndication | Lead or take an active syndicate role in our investments |
| Rights | No product rights or options are requested in our investment terms |
| Fund | SR One is structured as an evergreen fund |
| Deal Stats | $25-50MM invested annually in new and existing portfolio companies |
| Portfolio | More than 30 private and public companies |
| Capital | Over $500MM invested in the biotech space since 1985 |
| LPs | Structured as an independent subsidiary of GlaxoSmithKline (GSK), our sole investor |
| Firewall | We maintain a strict firewall with GSK regarding any confidential information |
2008 SR One Ltd